Morgan Stanley Infrastructure Partners Enters Into Agreement to Acquire Majority Stake in Nicollin Environnement

Morgan Stanley Infrastructure Partners Enters Into Agreement to Acquire Majority Stake in Nicollin Environnement

NEW YORK–(BUSINESS WIRE)–
Morgan Stanley Investment Management (MSIM), through investment funds managed by Morgan Stanley Infrastructure Partners (MSIP), its private infrastructure investment platform, today announced it has entered into exclusivity and committed to complete the acquisition of a majority stake in Nicollin Environnement (Nicollin or the Company), a family-owned French environmental platform focused on waste collection and sorting, urban street cleaning and water-related solutions. The Nicollin family will remain invested alongside MSIP and will continue to support the Company’s next phase of growth.

Founded in 1945 and led by the Nicollin family for more than three generations, the Company is one of France’s leading independent environmental platforms. Nicollin provides these essential environmental solutions to municipalities and businesses across France, operating through a national network of local centers. Nicollin manages approximately 360 public contracts and 8,000 private clients, supported by approximately 4,800 employees, a fleet of 2,900 vehicles, and a portfolio of strategically located, mission critical real property, including depots, transfer stations and sorting facilities.

“After more than 80 years of family ownership, we are proud to begin this next chapter with Morgan Stanley Infrastructure Partners, a partner that shares our vision for the future of Nicollin. Together, we will continue investing in growth, innovation and the environmental transition while preserving the values and culture that have shaped our company for three generations. By retaining an ownership stake, our family remains committed to supporting Nicollin and its teams for the long term,” said Olivier Nicollin and Laurent Nicollin.

MSIP will support Nicollin’s continued development, working alongside the Nicollin family and management team to advance operational excellence, renew and decarbonize the fleet, and strengthen its offerings to municipalities and corporate customers.

“We are thrilled at the prospect to partner with the Nicollin Family and management team through this strategic investment, which will support the next phase of the Company’s growth,” said Alfonso Gómez-Acebo, Managing Director at Morgan Stanley Infrastructure Partners. “Nicollin provides essential environmental solutions across France, supported by long-standing local relationships and a strong reputation for execution quality. We look forward to supporting the Company as it continues to invest in its people, fleet and infrastructure.”

“Nicollin is a strong fit with MSIP’s European infrastructure strategy, combining essential municipal solutions, resilient contractual revenues and clear opportunities to support the circular economy,” said Alberto Donzelli, Co-Head of Europe for Morgan Stanley Infrastructure Partners.

The transaction is expected to close in the fourth quarter of 2026 upon completion of the mandatory information and consultation procedures with employee representative bodies and customary regulatory approvals.

Paul Hastings served as legal counsel to MSIP, with Natixis Partners serving as financial advisor. Clifford Chance served as legal counsel to the Nicollin family, with Rothschild & Co serving as financial advisor.

About Nicollin Environment

Founded in 1945, Nicollin Environnement is today the leading independent, family-owned French group in the environmental services sector.

For more than 80 years, the Group has grown around the values at the heart of its identity: people, close ties with the local communities it serves, and pride in a job well done.

Present across France, Nicollin Environnement supports municipalities and businesses in waste management, urban cleaning, and water and sanitation services.

With more than 4,800 employees, the Group is organized around two complementary divisions: the Environment division (waste management and urban cleaning) and the Water division (water management and sanitation).

For further information about Nicollin Environnement, please visit www.groupenicollin.com.

About Morgan StanleyInfrastructure Partners

Morgan Stanley Infrastructure Partners (MSIP) is a leading global private infrastructure investment platform with approximately $17 billion in capital commitments since inception. Founded in 2006, MSIP has invested in a diverse portfolio across transportation, digital, energy transition, and water and waste. MSIP targets assets that provide essential public goods and services with the potential for value creation through active ownership. For further information about Morgan Stanley Infrastructure Partners, please visit Morgan Stanley Infrastructure Partners.

About Morgan Stanley Investment Management

Morgan Stanley Investment Management, together with its investment advisory affiliates, has more than 1,300 investment professionals around the world and $1.9 trillion in assets under management or supervision as of March 31, 2026. Morgan Stanley Investment Management strives to provide outstanding long-term investment performance, service, and a comprehensive suite of investment management solutions to a diverse client base, which includes governments, institutions, corporations and individuals worldwide. For further information about Morgan Stanley Investment Management, please visit www.morganstanley.com/im.

About Morgan Stanley

Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 42 countries, the Firm’s employees serve clients worldwide including corporations, governments, institutions and individuals. For further information about Morgan Stanley, please visit www.morganstanley.com.

Media Relations

Alyson Barnes: [email protected]

KEYWORDS: New York Europe United States North America France

INDUSTRY KEYWORDS: Finance Environment Recycling Professional Services Asset Management

MEDIA:

Yimutian Inc. Receives Positive Nasdaq Listing Determination

BEIJING, July 10, 2026 (GLOBE NEWSWIRE) — Yimutian Inc. (Nasdaq: YMT) (“Yimutian” or the “Company”), a leading agricultural digital service company in China, today announced that, following a hearing before the Nasdaq Hearings Panel (the “Panel”), on July 8, 2026, the Company received the Panel’s formal decision granting the Company’s request to transfer its listing from The Nasdaq Global Market tier to The Nasdaq Capital Market tier, pursuant to an exception to evidence compliance with the US$1.00 bid price and US$2.5 million stockholders’ equity requirements for continued listing on The Nasdaq Capital Market by September 29, 2026 and September 30, 2026, respectively.

The Company intends to take all necessary steps to timely satisfy the conditions set forth in the Panel decision and to evidence compliance with all applicable Nasdaq listing criteria as soon as practicable.

About Yimutian Inc.

Yimutian Inc. is a leading agricultural B2B platform in mainland China. Over a decade, the company has been dedicated to digitalizing China’s agricultural product supply chain infrastructure to streamline the agricultural product transaction process, and making it efficient, transparent, secure, and convenient.

For more information, please visit https://ir.ymt.com/.

Forward-Looking Statements

This press release contains forward-looking statements. These statements are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, these forward-looking statements can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

For investor inquiries, please contact:

Email: [email protected]

Phone: +86 1057086561

For media inquiries, please contact:

Email: [email protected] 



BW LPG Limited Announces Sale of BW Elm

BW LPG Limited Announces Sale of BW Elm

SINGAPORE–(BUSINESS WIRE)–
BW LPG Limited (“BW LPG” or the “Company”, OSE ticker code: “BWLPG.OL”, NYSE ticker code: “BWLP”) is pleased to announce that its 52%-owned subsidiary, BW LPG India, has entered into an agreement to sell the 2007-built BW Elm for continued trading.

On a 100% basis, the sale of BW Elm is expected to generate a net book gain of approximately US$36 million and net cash proceeds of around US$64 million. The vessel is scheduled for delivery to the buyer by mid-August.

Kristian Sørensen, CEO of BW LPG, says “By selling the BW Elm we continue capitalising on strong second-hand values for older vessels, selling a 2007-built asset at a level equivalent to a newbuilding price of about US$248 million. This reflects the strength and agility of our commercial platform and its ability to create value through opportunistic asset play as we are divesting older ships while investing in new tonnage”.

About BW LPG

BW LPG is the world’s leading owner and operator of LPG vessels, with a fleet of about 50 Very Large Gas Carriers (VLGCs), including over 20 vessels powered by LPG dual-fuel propulsion technology. Building on over five decades of LPG shipping experience, the company is strengthened by an in-house LPG trading division and the commercial expertise to explore investments in value chain assets. Together, these capabilities enable BW LPG to provide trusted and reliable services for sourcing and delivering LPG to customers worldwide. Delivering energy for a better world – more information about BW LPG can be found at www.bwlpg.com.

BW LPG is associated with BW Group, a leading global energy and maritime company involved in shipping, deepwater oil & gas production, renewable energy and digital infrastructure. BW controls a fleet of over 400 vessels transporting oil, gas and dry commodities. In the infrastructure space, the group operates in wind, batteries, water, subsea cable networks and data centres. www.bw-group.com

For further information, please contact:

Kristian Sørensen, CEO

Samantha Xu, CFO

[email protected]

KEYWORDS: Singapore Southeast Asia Asia Pacific

INDUSTRY KEYWORDS: Maritime Energy Transport Oil/Gas

MEDIA:

Logo
Logo

Australian Firms Shift Cybersecurity Focus to Resilience

Australian Firms Shift Cybersecurity Focus to Resilience

Organizations seek partners with local capabilities, including AI risk management and regulatory readiness, ISG Provider Lens® report says

SYDNEY–(BUSINESS WIRE)–
Enterprises in Australia are shifting cybersecurity strategies toward integrated, practical approaches that address evolving business risks and support safe, responsible AI adoption, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm.

The 2026 ISG Provider Lens® Cybersecurity — Services and Solutions report for Australia finds that enterprises are placing greater importance on cybersecurity capabilities delivered within Australia as they respond to rising regulatory expectations, expanding AI risks and increasingly complex threat environments. Organizations are seeking partners that can strengthen long-term resilience across cloud environments, identity infrastructure and critical infrastructure.

“Australian enterprises increasingly expect cybersecurity partners to combine proven local delivery with practical capabilities to address evolving regulatory expectations,” said Michael Gale, partner and regional leader, ISG Asia Pacific. “Organizations are placing greater value on providers that understand Australia’s operating environment and can support critical business functions close to home.”

Companies in Australia are adopting AI-enabled security capabilities to improve operational efficiency and strengthen security workflows. Organizations are using AI to enhance threat detection, accelerate prioritization and streamline case management while reducing pressure on security teams. They favor practical applications that strengthen day-to-day security operations rather than broad technology narratives.

Organizations are placing greater emphasis on managing the risks associated with expanding use of generative AI and agentic AI. As AI becomes embedded in business processes, enterprises are reinforcing data protection, access controls and oversight to address legal, operational and reputational risks. They increasingly expect cybersecurity partners to support responsible AI adoption alongside stronger security practices.

Regulatory requirements continue to reshape enterprise cybersecurity priorities across Australia. Organizations involved in critical infrastructure, financial services, healthcare, telecommunications and government are increasing investments in incident response, recovery planning and third-party risk management. Consolidation of overlapping technologies is simplifying security operations and increasing visibility across organizations. Enterprises expect integrated delivery models to connect strategic planning with day-to-day operations, ISG says.

“Australian companies are becoming much more disciplined in how they evaluate cybersecurity partners,” said Andrew Milroy, lead author of the report. “Providers that combine practical AI expertise with strong execution and sector knowledge are best positioned to meet enterprise expectations.”

The report also explores other trends in Australia’s cybersecurity market, including the growing use of threat-led assessments and tabletop exercises to strengthen preparedness and increasing enterprise interest in commercial models that deliver greater flexibility and faster time to value.

For more insights into the cybersecurity challenges faced by enterprises in Australia, along with ISG’s advice for overcoming them, see the ISG Provider Lens Focal Points briefing here.

The report evaluates the capabilities of 36 providers across three quadrants: Strategic Security Services, Technical Security Services and Next-Gen SOC/MDR Services.

It names Accenture, Deloitte, DXC Technology, EY, Fujitsu, HCLTech, IBM, NTT DATA, TCS, Thales and Wipro as Leaders in all three quadrants. Infosys and PwC are named as Leaders in two quadrants each, and KPMG, Tech Mahindra and Telstra are named as Leaders in one quadrant each.

In addition, Brennan is named as a Rising Star — a company with a “promising portfolio” and “high future potential” by ISG’s definition — in two quadrants. Datacom is named as a Rising Star in one quadrant.

In the area of customer experience, EY is named the global ISG CX Star Performer for 2026 among cybersecurity service and solution providers. EY earned the highest customer satisfaction scores in ISG’s Voice of the Customer survey, which is part of the ISG Star of Excellence™ program, the premier quality recognition for the technology and business services industry.

The 2026 ISG Provider Lens Cybersecurity — Services and Solutions report for Australia is available to subscribers or for one-time purchase on this webpage.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data and research, in-depth knowledge and governance of provider ecosystems, and the expertise of its 1,500 professionals worldwide working together to help clients maximize the value of their technology investments.

Press Contacts:

Laura Hupprich, ISG

+1 203-517-3132

[email protected]

Erik Arvidson, Matter Communications for ISG

+1 978-518-4542

[email protected]

KEYWORDS: Australia/Oceania Australia Asia Pacific

INDUSTRY KEYWORDS: Technology Consulting Security Professional Services Software Internet Electronic Design Automation Data Management Artificial Intelligence

MEDIA:

Logo
Logo

Cue Biopharma Announces $50.0 Million Private Placement

BOSTON, July 09, 2026 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 1,418,071 shares of common stock at a purchase price of $33.21 per share and (ii) to certain investors, in lieu of shares of common stock, pre-funded warrants to purchase up to 87,500 shares of common stock at a price per pre-funded warrant of $33.209, for gross proceeds of approximately $50.0 million.

The private placement is expected to close on or about July 13, 2026, subject to the satisfaction of customary closing conditions. The pre-funded warrants will have an exercise price of $0.001 per share, be immediately exercisable, and remain exercisable until exercised in full.

The private placement was led by Cormorant Asset Management, with participation from additional new investment funds including Columbia Threadneedle Investments.

The Company intends to use the net proceeds from the private placement to further fund clinical development and for other general corporate purposes.

“We are pleased to have such a high-quality group of biotech investors committing to the long-term support of Cue as we build our company and advance our portfolio targeting functional cures across immunological disorders,” said Shao-Lee Lin, M.D., Ph.D., chief executive officer, president and board director of Cue Biopharma. “We look forward to our upcoming clinical milestones, including data from Ascendant Health’s ongoing Phase 2 CSU study in China, which is expected by the end of the third quarter of 2026.”

The securities being issued and sold in the private placement, including the shares of common stock underlying the pre-funded warrants, have not been registered under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. Concurrently with the execution of the securities purchase agreement, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock sold in the private placement and the shares of common stock underlying the pre-funded warrants sold in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.

About Cue Biopharma

Cue Biopharma (Nasdaq: CUE) is a clinical stage biopharmaceutical company focused on advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its lead asset is a novel anti-IgE antibody with a dual-mechanism of action, currently in Phase 2 development for allergic diseases. In addition, Cue developed the Immuno-STAT® platform which selectively targets disease-specific T cells in vivo without broad immune modulation. Its lead autoimmune candidate, CUE-401, is advancing towards Phase 1 and was designed to regulate inflammation and drive Treg-mediated tolerance. Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the expected closing of, and anticipated use of proceeds from, the private placement and the company’s anticipated clinical milestones. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,” “promise” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, market conditions and the satisfaction of customary closing conditions related to the private placement, and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor and Media Contact

Agnes Lee
Chief Officer of Public and Investor Relations

Marie Campinell
Senior Director, Corporate Communications

[email protected]

Cue Biopharma, Inc.



Public Storage Prices Public Offering of $900 Million of Senior Notes at an Effective Interest Rate of 4.855% to Fund the Acquisition of National Storage Affiliates Trust

Public Storage Prices Public Offering of $900 Million of Senior Notes at an Effective Interest Rate of 4.855% to Fund the Acquisition of National Storage Affiliates Trust

FRISCO, Texas–(BUSINESS WIRE)–
Public Storage (NYSE:PSA, the “Company”) announced today that the Company’s subsidiary, Public Storage Operating Company (“PSOC”), has priced a public offering of $900 million aggregate principal amount of fixed-rate senior notes (the “Notes”). The Notes will be guaranteed by the Company.

The Notes will be issued in two tranches with a weighted average effective interest rate of 4.855%, inclusive of the impact of the interest rate swaps noted below. The first tranche of $400 million aggregate principal amount of fixed-rate senior notes due 2032 will bear interest at an annual rate of 4.700%, will be issued at 99.283% of par value and will mature on February 1, 2032 (the “2032 Notes”). The second tranche of $500 million aggregate principal amount of fixed-rate senior notes due 2036 will bear interest at an annual rate of 5.150%, will be issued at 98.553% of par value and will mature on August 15, 2036 (the “2036 Notes”). Including the impact of prior interest rate swaps, the effective interest rate of the 2036 Notes will be 4.979%. PSOC will pay interest on the 2032 Notes semi-annually on February 1 and August 1 of each year, commencing February 1, 2027, and will pay interest on the 2036 Notes semi-annually on February 15 and August 15 of each year, commencing February 15, 2027.

The offering is expected to close on July 20, 2026, subject to the satisfaction of customary closing conditions. PSOC expects to use the net proceeds to finance, in part, the Company’s pending acquisition of National Storage Affiliates Trust (“NSA”), which may include the payment of related fees and expenses, and for general corporate purposes, including to make investments in self-storage facilities (such as acquisitions of facilities or interests in entities that own facilities, development, and mortgage loans secured by facilities), the repayment of debt and the redemption of outstanding securities.

The sale of Notes in this offering is not contingent upon the completion of the NSA acquisition, which, if completed, is expected to occur soon after the closing of this offering. However, in the event that the NSA acquisition is not consummated, we will be required to redeem the Notes then outstanding at a redemption price equal to 101% of the principal amount of the Notes being redeemed plus accrued and unpaid interest.

Goldman Sachs & Co. LLC and Wells Fargo Securities, LLC acted as joint book-running managers of the offering. This announcement shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any offer or sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. The offering is being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the “SEC”) and only by means of a prospectus and prospectus supplement. Investors may obtain these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, copies of the prospectus and prospectus supplement may be obtained by contacting Goldman Sachs & Co. LLC toll-free at 1-866-471-2526 or Wells Fargo Securities, LLC toll-free at 1-800-645-3751.

About Public Storage

Public Storage, a member of the S&P 500, is a REIT that primarily acquires, develops, owns, and operates self-storage facilities. At March 31, 2026, the Company: (i) owned and/or operated 3,546 self-storage facilities located in 40 states with approximately 259 million net rentable square feet in the United States and (ii) owned a 35% common equity interest in Shurgard Self Storage Limited (Euronext Brussels: SHUR), which owned 333 self-storage facilities located in seven Western European countries with approximately 19 million net rentable square feet operated under the Shurgard® brand. Public Storage is headquartered in Frisco, Texas.

Forward-Looking Statements

When used within this press release, the words “expects,” “believes,” “anticipates,” “plans,” “would,” “should,” “may,” “estimates” and similar expressions are intended to identify “forward-looking statements,” including but not limited to, statements about the completion and timing of the proposed offering of securities by the Company, the intended use of net proceeds of such offering, and the consummation of the NSA acquisition. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results to be materially different from those expressed or implied in the forward-looking statements. Such factors include market conditions and the demand for the Company’s securities and risks detailed in the Company’s prospectus and prospectus supplement filed with the SEC in connection with this offering and in the Company’s SEC reports, including quarterly reports on Form 10-Q, current reports on Form 8-K and annual reports on Form 10-K. We undertake no obligation to publicly update or revise forward-looking statements which may be made to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, except as required by law.

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Other Construction & Property Commercial Building & Real Estate Construction & Property REIT

MEDIA:

Logo
Logo

AstraZeneca Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into AstraZeneca (AZN)

PR Newswire

AstraZeneca (AZN) announced its key CARDIO-TTRansform Phase III trial missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities claims on behalf of affected AZN investors.

NEW YORK, July 9, 2026 /PRNewswire/ — AstraZeneca PLC (NYSE: AZN) faces a securities investigation after shares fell more than 8.3% in early trading on July 9, 2026. If you purchased AstraZeneca shares and suffered a loss, you are encouraged to check your eligibility to recover losses now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

Levi & Korsinsky, LLP

Wainua, a gene-silencing drug for transthyretin-mediated amyloid cardiomyopathy, had been positioned as a key value driver toward AstraZeneca’s stated “$80 billion 2030 ambition.” The Company referred to the trial as the “largest trial in this population” with the “potential to address key questions” unanswered in the community.

On July 9, 2026, AstraZeneca reported that the trail had failed, noting that “adding Wainua did not provide a statistically significant benefit on the composite outcome of CV mortality and recurrent CV events.”

If you purchased AstraZeneca shares and lost money, submit your information to preserve your rights. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

WHY LEVI & KORSINSKY — Ranked in ISS Securities Class Action Services’ Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.

Frequently Asked Questions About the AZN Investigation

Q: Who is conducting the AZN investigation? A: Levi & Korsinsky, LLP is investigating potential securities fraud claims on behalf of investors who purchased AZN securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.

Q: What is the AZN securities fraud investigation about? A securities investigation is pending concerning AstraZeneca (NYSE: AZN) regarding potentially materially false or misleading statements. Shares fell over 8.3% premarket after the Company disclosed that the Phase III CARDIO-TTransform trial of Wainua missed its primary endpoint, causing losses for shareholders.

Q: Who is eligible to participate in the AZN investigation? A: Investors who purchased AZN stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.

Q: What do AZN investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my AZN shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought AZN and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis. No upfront fees, no retainer, and no out-of-pocket costs.

Q: What if I live outside the United States? A: U.S. securities fraud investigations generally cover purchases on U.S. exchanges regardless of the investor’s country of residence.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/astrazeneca-investigation-notice-levi–korsinsky-notifies-investors-of-pending-investigation-into-astrazeneca-azn-302822392.html

SOURCE Levi & Korsinsky, LLP

Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of a Pending Investigation Into Ionis Pharmaceuticals (IONS)

PR Newswire

Ionis Pharmaceuticals told investors its CARDIO-TTRansform program was on track to deliver landmark data — then the Phase-3 trial missed its primary endpoint. Levi & Korsinsky is investigating.

NEW YORK, July 9, 2026 /PRNewswire/ — Ionis Pharmaceuticals (NASDAQ: IONS) shares were falling more than 20% on July 9, 2026, after the Company disclosed that its Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint. If you purchased IONS shares and suffered a loss, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

Levi & Korsinsky, LLP

The investigation concerns whether the Company’s prior public statements regarding the CARDIO-TTRansform program aligned with the trial’s ultimate outcome. On November 6, 2024, CEO Brett Monia stated on the Company’s Q3 2024 earnings call that the “ongoing CARDIO-TTRansform trial [was] on track to deliver the most comprehensive dataset in these patients in the second half of 2026.” More recently, on June 10, 2026, CEO Monia reiterating that data was expected in the back half of the year, told investors “everything is going very well in the conduct of the study and the execution. The study is reasonably derisked for its primary endpoint. We’re excited.”

On July 9, 2026, the company disclosed that its trial, partnered with AstraZeneca, did not meet its primary endpoint of reducing combined cardiovascular death and recurrent events in transthyretin-mediated amyloid cardiomyopathy patients. The stock opened down more than 20% on the news. Levi & Korsinsky is investigating potential securities law violations on behalf of IONS investors.

Shareholders who lost money on IONS are encouraged to contact the firm to discuss their legal rights. You may also reach Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

WHY LEVI & KORSINSKY — Ranked in ISS Securities Class Action Services’ Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.

Frequently Asked Questions About the IONS Investigation

Q: What is the IONS securities fraud investigation about? A: A securities investigation is pending concerning Ionis Pharmaceuticals (NASDAQ: IONS) regarding potentially materially false or misleading statements. Shares opened down more than 20% on July 9, 2026, after the Company disclosed that its Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint, causing losses for shareholders.

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Ionis made materially false or misleading statements regarding the status and expected results of its CARDIO-TTRansform program. When the Company disclosed the trial’s failure to meet its primary endpoint, the stock price declined sharply.

Q: Who is eligible to participate in the IONS investigation? A: Investors who purchased IONS stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.

Q: What do IONS investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.

Q: What is a lead plaintiff and why does it matter? A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.

Q: What if I already sold my IONS shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought IONS and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis. No upfront fees, no retainer, and no out-of-pocket costs.

Q: What if I live outside the United States? A: U.S. securities fraud investigations generally cover purchases on U.S. exchanges regardless of the investor’s country of residence.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-pharmaceuticals-investigation-notice-levi–korsinsky-notifies-investors-of-a-pending-investigation-into-ionis-pharmaceuticals-ions-302822333.html

SOURCE Levi & Korsinsky, LLP

Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026

Continued Growth Underpins First Full Year Net Revenue of US$115M 

NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net revenue of US$36 million for the quarter and US$115 million for the full year ended June 30, 2026. “We are very pleased with the strong uptake of Ryoncil® since launch, and with revenues that have already exceeded our initial projections,” said Mesoblast Chief Executive Dr. Silviu Itescu.

Dr. Itescu added: “We anticipate continued revenue growth in the coming fiscal year in line with momentum we are seeing across major U.S. pediatric centers. Our capital position is strong, operational activities are well funded through revenue growth, and the new five-year facility has freed up our label extension and blockbuster products for strategic initiatives.”

Ryoncil® is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food and Drug Administration (FDA) for any indication and is the only FDA-approved product for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD).1

The results presented herein are based on management’s preliminary estimates and remain subject to completion of customary year end closing and audit procedures.

About Mesoblast

Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.

About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.

About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

References / Footnotes

  1. Please see the full Prescribing Information at www.ryoncil.com

Forward-Looking Statements

This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For more information, please contact:


Corporate Communications / Investors
 
Paul Hughes  
T: +61 3 9639 6036  
   

Media – Global

Media – Australia
Rubenstein BlueDot Media
Caroline Nelson Steve Dabkowski
T: +1 703 489 3037 T: +61 419 880 486
E: [email protected] E: [email protected]



VRRM Investors Have Opportunity to Lead Verra Mobility Corporation Securities Fraud Lawsuit

PR Newswire

NEW YORK, July 9, 2026 /PRNewswire/ —

Rosen Law Firm Logo

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Verra Mobility Corporation (NASDAQ: VRRM) between February 24, 2026 and May 26, 2026, inclusive (the “Class Period”), of the important August 4, 2026 lead plaintiff deadline.

So what: If you purchased Verra Mobility common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Verra Mobility class action, go to https://rosenlegal.com/cases/verra-mobility-corporation-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 4, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Verra’s relationship with Avis Budget Group (“Avis”), and in particular obtaining a contract extension with Avis. Further, the Company minimized concerns that major rent-a-cars could replace Verra with in-house solutions or outsourced alternatives. When the true details entered the market, the lawsuit claims that investors suffered damages. 

To join the Verra Mobility class action, go to https://rosenlegal.com/cases/verra-mobility-corporation-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/vrrm-investors-have-opportunity-to-lead-verra-mobility-corporation-securities-fraud-lawsuit-302822310.html

SOURCE THE ROSEN LAW FIRM, P. A.